Disease · MONDO_0006861
myeloid sarcoma
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. myeloid sarcoma. Diseases, record MONDO_0006861. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006861
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- chloroma, extramedullary myeloid tumor, extramedullary myeloid tumour, granulocytic sarcoma, sarcoma, myeloid, malignant
- Open Targets
Drugs12
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| AZACITIDINE | CHEMBL1489 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CYTARABINE | CHEMBL803 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| VENETOCLAX | CHEMBL3137309 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DAUNORUBICIN | CHEMBL178 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DECITABINE | CHEMBL1201129 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GEMTUZUMAB | CHEMBL2108342 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GLASDEGIB | CHEMBL2043437 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IDARUBICIN | CHEMBL1117 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MIDOSTAURIN | CHEMBL608533 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MITOXANTRONE | CHEMBL58 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 12
See all 12 drugsTargets33
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| TOP2A | DNA topoisomerase 2-alpha | 4 | DNA topoisomerase II alpha inhibitor | Phase 2 | https://conductscience.org/library/genes/7153 | Drugs and targets |
| DNMT1 | DNA (cytosine-5)-methyltransferase 1 | 2 | DNA (cytosine-5)-methyltransferase 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1786 | Drugs and targets |
| DNMT3A | DNA (cytosine-5)-methyltransferase 3A | 2 | DNA (cytosine-5)-methyltransferase 3A inhibitor | Phase 2 | https://conductscience.org/library/genes/1788 | Drugs and targets |
| BCL2 | Apoptosis regulator Bcl-2 | 1 | Apoptosis regulator Bcl-2 inhibitor | Phase 2 | https://conductscience.org/library/genes/596 | Drugs and targets |
| CD33 | Myeloid cell surface antigen CD33 | 1 | Myeloid cell surface antigen CD33 binding agent | Phase 2 | https://conductscience.org/library/genes/945 | Drugs and targets |
| FLT3 | Receptor-type tyrosine-protein kinase FLT3 | 1 | Tyrosine-protein kinase receptor FLT3 inhibitor | Phase 2 | https://conductscience.org/library/genes/2322 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor 2 | 1 | Vascular endothelial growth factor receptor 2 inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 1 | Stem cell growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRA | Platelet-derived growth factor receptor | 1 | Platelet-derived growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/5156 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 1 | Platelet-derived growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/5159 | Drugs and targets |
1 to 10 of 33
See all 33 targetsTrials3
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03226418 | Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia | Phase 2 | 75 | 2025-11-05 | Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia | AZACITIDINE, CYTARABINE, DAUNORUBICIN, DECITABINE, GEMTUZUMAB, GLASDEGIB, IDARUBICIN, MIDOSTAURIN, VENETOCLAX | Its record names the disease | ClinicalTrials.gov |
| NCT02484391 | CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma | Phase 1 | 48 | 2024-09-19 | Granulocytic Sarcoma, Recurrent Adult Acute Myeloid Leukemia | CYTARABINE, MITOXANTRONE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT07028086 | VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma | Phase 2 | 48 | Acute Myeloid Leukemia, Myeloid Sarcoma | AZACITIDINE, MITOXANTRONE, VENETOCLAX | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Group I vs Group II: Mortality at 90 Days | 1 of 8 | 15 of 65 | 73 | NCT03226418 | Trial comparisons |
| Group I vs Group II: deaths from any cause | 1 of 8 | 15 of 65 | 73 | NCT03226418 | Trial comparisons |
| Group I vs Group II: serious adverse events | 5 of 8 | 41 of 65 | 73 | NCT03226418 | Trial comparisons |
Papers from its trials4
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006861
GET https://conductscience.org/api/diseases/v1/MONDO_0006861/targets?page=2